An Adjustable Dalteparin Sodium Dose Regimen for the Prevention of Clotting in the Extracorporeal Circuit in Hemodialysis: A Clinical Trial of Safety and Efficacy (the PARROT Study).

ABSTRACT:

Background

Dalteparin sodium, a low-molecular-weight heparin, is indicated for prevention of clotting in the extracorporeal circuit during hemodialysis (HD). Product labeling recommends a fixed single-bolus dose of 5000 international units (IU) for HD sessions lasting up to 4 hours, but adjustable dosing may be beneficial in clinical practice.

Objective

The aim of the PARROT study was to investigate the safety and efficacy of an adjustable dose of dalteparin in patients with end-stage renal disease requiring 3 to 4 HD sessions per week.

Design

A 7-week, open-label, multicenter study with a single treatment arm, conducted between October 2013 and March 2016.

Setting

Ten sites in Canada.

Patients

A total of 152 patients with end-stage renal disease requiri

SUBMITTER: Soroka S 

PROVIDER: S-EPMC6236648 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature